JP2019531254A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019531254A5 JP2019531254A5 JP2018565319A JP2018565319A JP2019531254A5 JP 2019531254 A5 JP2019531254 A5 JP 2019531254A5 JP 2018565319 A JP2018565319 A JP 2018565319A JP 2018565319 A JP2018565319 A JP 2018565319A JP 2019531254 A5 JP2019531254 A5 JP 2019531254A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- binding fragment
- pharmaceutical composition
- humanized
- humanized antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000012634 fragment Substances 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 10
- 201000011510 cancer Diseases 0.000 claims description 10
- 101000830689 Homo sapiens Protein tyrosine phosphatase type IVA 3 Proteins 0.000 claims description 8
- 101000835900 Homo sapiens Submaxillary gland androgen-regulated protein 3B Proteins 0.000 claims description 8
- 102100024601 Protein tyrosine phosphatase type IVA 3 Human genes 0.000 claims description 8
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 8
- 206010017758 gastric cancer Diseases 0.000 claims description 8
- 201000011549 stomach cancer Diseases 0.000 claims description 8
- 230000000340 anti-metabolite Effects 0.000 claims description 6
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 229940100197 antimetabolite Drugs 0.000 claims description 6
- 239000002256 antimetabolite Substances 0.000 claims description 6
- 238000002560 therapeutic procedure Methods 0.000 claims description 6
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 206010027476 Metastases Diseases 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 210000000987 immune system Anatomy 0.000 claims description 2
- 230000001771 impaired effect Effects 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000009401 metastasis Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 8
- 239000000203 mixture Substances 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 6
- 238000011319 anticancer therapy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022033194A JP7408707B2 (ja) | 2016-06-14 | 2022-03-04 | Ｐｒｌ３抗体 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SG10201604834P | 2016-06-14 | ||
| SG10201604834P | 2016-06-14 | ||
| PCT/SG2017/050300 WO2017217934A1 (en) | 2016-06-14 | 2017-06-14 | Prl3 antibody |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033194A Division JP7408707B2 (ja) | 2016-06-14 | 2022-03-04 | Ｐｒｌ３抗体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2019531254A JP2019531254A (ja) | 2019-10-31 |
| JP2019531254A5 true JP2019531254A5 (enExample) | 2020-06-18 |
Family
ID=60663634
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018565319A Pending JP2019531254A (ja) | 2016-06-14 | 2017-06-14 | Ｐｒｌ３抗体 |
| JP2022033194A Active JP7408707B2 (ja) | 2016-06-14 | 2022-03-04 | Ｐｒｌ３抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022033194A Active JP7408707B2 (ja) | 2016-06-14 | 2022-03-04 | Ｐｒｌ３抗体 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US11155636B2 (enExample) |
| EP (1) | EP3469003A4 (enExample) |
| JP (2) | JP2019531254A (enExample) |
| KR (1) | KR102451588B1 (enExample) |
| CN (1) | CN109476759B (enExample) |
| AU (1) | AU2017285995B2 (enExample) |
| BR (1) | BR112018075901A2 (enExample) |
| CA (1) | CA3025756A1 (enExample) |
| SG (1) | SG11201811068YA (enExample) |
| WO (1) | WO2017217934A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2023219091A1 (ja) | 2022-05-11 | 2023-11-16 | 国立研究開発法人産業技術総合研究所 | アンモニア分離膜及びそれを用いたアンモニア分離方法 |
| WO2025116819A1 (en) * | 2023-11-30 | 2025-06-05 | Agency For Science, Technology And Research | Methods of treating neovascular eye diseases |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050287644A1 (en) * | 2004-05-14 | 2005-12-29 | Genesis Biotech Inc. | Methods for producing and culturing rabbit-mouse hybridomas and monoclonal antibodies secreted by rabbit-mouse hybridomas |
| US7462697B2 (en) * | 2004-11-08 | 2008-12-09 | Epitomics, Inc. | Methods for antibody engineering |
| WO2006091326A1 (en) * | 2005-01-28 | 2006-08-31 | Attogen Inc. | Anti-prl-3 antibodies and methods of use thereof |
| CN101820910B (zh) * | 2007-05-03 | 2014-08-06 | 新加坡科技研究局 | 结合细胞内prl-1多肽或prl-3多肽的抗体 |
| JP2012505654A (ja) * | 2008-10-14 | 2012-03-08 | ヤンセン バイオテツク，インコーポレーテツド | 抗体をヒト化及び親和性成熟する方法 |
| WO2011065923A1 (en) * | 2009-11-30 | 2011-06-03 | Agency For Science, Technology And Research | Treatment and prevention of cancers associated with intracellular oncoproteins by antibody therapy or vaccination |
| US20170146538A1 (en) * | 2014-02-07 | 2017-05-25 | Agency For Science, Technology And Research | Prl-3 as a biomarker for the prognosis of cancer and a target for therapy |
-
2017
- 2017-06-14 JP JP2018565319A patent/JP2019531254A/ja active Pending
- 2017-06-14 US US16/309,439 patent/US11155636B2/en active Active
- 2017-06-14 AU AU2017285995A patent/AU2017285995B2/en active Active
- 2017-06-14 BR BR112018075901-5A patent/BR112018075901A2/pt unknown
- 2017-06-14 KR KR1020197001195A patent/KR102451588B1/ko active Active
- 2017-06-14 EP EP17813707.1A patent/EP3469003A4/en active Pending
- 2017-06-14 CN CN201780037479.8A patent/CN109476759B/zh active Active
- 2017-06-14 CA CA3025756A patent/CA3025756A1/en active Pending
- 2017-06-14 SG SG11201811068YA patent/SG11201811068YA/en unknown
- 2017-06-14 WO PCT/SG2017/050300 patent/WO2017217934A1/en not_active Ceased
-
2022
- 2022-03-04 JP JP2022033194A patent/JP7408707B2/ja active Active